MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Hemispherx BioPharma Company Profile (NYSE:HEB)

Consensus Ratings for Hemispherx BioPharma (NYSE:HEB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Hemispherx BioPharma (NYSE:HEB)
Show:
DateFirmActionRatingPrice TargetActions
4/2/2015Midtown PartnersInitiated CoverageStrong-Buy$1.45View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Hemispherx BioPharma (NYSE:HEB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/9/2015        
5/16/2016Q116($0.01)$40.99 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q2($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q1 15($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2013Q2 2013($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Hemispherx BioPharma (NYSE:HEB)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Hemispherx BioPharma (NYSE:HEB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Hemispherx BioPharma (NYSE:HEB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/18/2016Thomas K EquelsCEOBuy30,000$0.13$3,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Thomas K EquelsCEOBuy40,000$0.16$6,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2016Thomas K EquelsCEOBuy30,000$0.16$4,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015Thomas K EquelsCFOBuy79,104$0.18$14,238.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015William A CarterCEOBuy73,681$0.23$16,946.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2015William A CarterCEOBuy26,319$0.23$6,053.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Thomas K EquelsCFOBuy100,000$0.23$23,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Hemispherx BioPharma (NYSE:HEB)
DateHeadline
06/20/16 03:17 PMHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers -
06/20/16 10:36 AMHot Alert: Approach Resources, Inc. (NASDAQ:AREX), Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Rocket Fuel Inc ... - KC Register
06/16/16 08:43 AMTraded Price Fluctuations to Observe: Sanofi (NYSE:SNY) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB) - Street Updates
06/13/16 04:07 PMTake a look at Price Moves: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB) - Street Updates
06/10/16 04:35 PMSummary of Price Movements: Hemispherx BioPharma, Inc. (NYSEMKT:HEB) , EXACT Sciences Corporation ... - Street Updates
06/10/16 03:18 PMHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year -
06/09/16 04:32 PMHemispherx Biopharma, Inc. (NYSEMKT:HEB) surged 8.83%: Galena Biopharma Inc (NASDAQ:GALE), Verizon ... - KC Register
06/09/16 04:32 PMHemispherx BioPharma, (NYSEMKT:HEB) & UnitedHealth Group (NYSE:UNH) Healthcare Stocks on the Move - Wall Street 24
06/09/16 04:32 PMAnalyst's Valuable Buzzers: Rock Creek Pharmaceuticals, Inc. (NASDAQ:RCPI) , Hemispherx BioPharma, Inc ... - Street Updates
06/09/16 07:01 AMHemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance…
06/09/16 07:01 AMLatest Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Target Price Suggests Stock Is Worth $0.96/Share
06/08/16 04:39 PMHemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation ... - GlobeNewswire (press release)
06/08/16 03:23 PMHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/08/16 07:03 AMHemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment ... - Nasdaq
06/07/16 04:32 PMHemispherx gets IP rights from the CEO it fired - Philadelphia Business Journal
06/07/16 10:40 AMHemispherx gets IP rights from the CEO it fired -
06/07/16 07:48 AMHemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology - [at noodls] - Article Reviews the History of Drug Development, Patient Clinical Trials, and Evaluates Toxicity of the Product PHILADELPHIA, June 07, 2016 (GLOBE NEWSWIRE) -- Dr. William Mitchell, M.D., Ph.D., Chairman ...
06/07/16 07:30 AMHemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology - [GlobeNewswire] - PHILADELPHIA, June 07, 2016-- Dr. William Mitchell, M.D., Ph.D., Chairman of the Board of Directors for Hemispherx Biopharma and a Professor of Pathology, Microbiology and Immunology at Vanderbilt University, ...
06/06/16 04:19 PMHemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property - GlobeNewswire (press release)
06/06/16 07:38 AMHemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property - [at noodls] - PHILADELPHIA, June 06, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that on June 2, 2016 it obtained an omnibus assignment of all Intellectual Property rights (IP) ...
06/03/16 07:03 AMHemispherx Biopharma Incorporated (NYSEMKT:HEB) Sellers Increased By 50.87% Their Shorts - HNN - Hemispherx Biopharma Incorporated (NYSEMKT:HEB) Sellers Increased By 50.87% Their ShortsHNNThe short interest to Hemispherx Biopharma Incorporated's float is 0.21%. The stock decreased 4.09% or $0.005 on June 2, hitting $0.115. About 526,223 shares traded hands or 22.43% up from the average. Hemispherx BioPharma, Inc (NYSEMKT:HEB) has ...
06/01/16 04:44 PMHealthcare Stocks in Concern: AbbVie Inc. (NYSE:ABBV) , Hemispherx Biopharma (NYSEMKT:HEB), Cellectar ... - Street Wise Report (press release) (blog) - Healthcare Stocks in Concern: AbbVie Inc. (NYSE:ABBV) , Hemispherx Biopharma (NYSEMKT:HEB), Cellectar ...Street Wise Report (press release) (blog)AbbVie Inc. (NYSE:ABBV) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 0.35% to $62.93. AbbVie (ABBV) released that the European Commission permitted IMBRUVICA (ibrutinib) as a first-line ...
05/31/16 04:34 PMHemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm - EIN News (press release) - Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP PharmEIN News (press release)/EIN News/ -- PHILADELPHIA, May 31, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it executed a renewed Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latino ...
05/31/16 04:34 PMHemispherx Biopharma Inc.: Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement ... - The Wall Street Transcript - Hemispherx Biopharma Inc.: Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement ...The Wall Street TranscriptPHILADELPHIA, May 31, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it executed a renewed Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latino America (GP ...Hemispherx Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm (NYSEMKT:HEB)Sonoran Weekly Reviewall 2 news articles »
05/31/16 07:52 AMHemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm - [at noodls] - Initial Target is ANMAT Approval to Treat Chronic Fatigue Syndrome Patients in Argentina PHILADELPHIA, May 31, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma. Inc. (NYSE MKT:HEB) announced today that it ...
05/26/16 12:24 PMHemispherx BioPharma : UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe - (GlobeNewswire) - Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended ... 05/17 HEMISPHERX BIOPHARMA INC: Results of Operations and Financial Condition, Regula.. 05/16 Hemispherx Biopharma Announces Financial Results for ...
05/25/16 10:59 AMHemispherx BioPharma : Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe - (GlobeNewswire) - Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended ... 05/16 HEMISPHERX BIOPHARMA INC: Results of Operations and Financial Condition, Regula.. 05/16 Hemispherx Biopharma Announces Financial Results for ...
05/25/16 09:14 AMHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events -
05/24/16 11:36 AMUPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe - [at noodls] - PHILADELPHIA, May 24, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based company ...
05/23/16 07:46 AMHemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe - [at noodls] - PHILADELPHIA, May 23, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based company ...
05/22/16 12:38 PMRevenue Update on Hemispherx BioPharma Inc(NYSEMKT:HEB) - Trade Calls - Revenue Update on Hemispherx BioPharma Inc(NYSEMKT:HEB)Trade CallsHemispherx BioPharma Inc(NYSEMKT:HEB) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 16, 2016. Earnings per share were $-0.01. Hemispherx BioPharma Inc (HEB) made into the market ...
05/19/16 10:49 AMInsiders Are Buying Hemispherx Biopharma, Inc. (:HEB) - Wall Street Hints and News - Insiders Are Buying Hemispherx Biopharma, Inc. (:HEB)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Hemispherx Biopharma, Inc. (:HEB) have increased their position in the stock by 7.30%. Insiders now own 0.60% of total outstanding shares. There are both legal and illegal types of insider trading ...and more »
05/19/16 10:49 AMHemispherx Biopharma Inc (NYSEMKT:HEB) Q4 2015 Institutional Investor Sentiment Steady - Wall Street Hints and News - Hemispherx Biopharma Inc (NYSEMKT:HEB) Q4 2015 Institutional Investor Sentiment SteadyWall Street Hints and NewsHemispherx Biopharma Inc (NYSEMKT:HEB) institutional sentiment decreased to 1 in 2015 Q4. Its down -2.00, from 3 in 2015Q3. The ratio is negative, as 6 hedge funds started new and increased holdings, while 6 sold and reduced equity positions in ...
05/16/16 09:45 PMHemispherx Biopharma Inc.: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March ... - The Wall Street Transcript - Hemispherx Biopharma Inc.: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March ...The Wall Street TranscriptPHILADELPHIA, May 16, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2016. The net loss was approximately $2,164,000 or $(0.01) per share as compared to a ...and more »
05/16/16 05:12 PMHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure -
05/16/16 04:42 PMHemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2016 - [at noodls] - The company is now focusing on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the world. ...
05/16/16 01:26 PMHemispherx Biopharma Incorporated (NYSEMKT:HEB) Sellers Covered 38.87% of Their Shorts - Wall Street Hints and News - Hemispherx Biopharma Incorporated (NYSEMKT:HEB) Sellers Covered 38.87% of Their ShortsWall Street Hints and NewsThe short interest to Hemispherx Biopharma Incorporated's float is 0.14%. The stock increased 0.91% or $0.001 on May 13, hitting $0.111. About 222,534 shares traded hands. Hemispherx BioPharma, Inc (NYSEMKT:HEB) has declined 31.25% since October ...and more »
05/13/16 05:24 AMHemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on May 17, 2016 - GlobeNewswire (press release) - Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on May 17, 2016GlobeNewswire (press release)PHILADELPHIA, May 12, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 first quarter financial results for quarter ended March 31 on Monday, ...
05/12/16 07:47 AMHemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on May 17, 2016 - [at noodls] - PHILADELPHIA, May 12, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the 'Company' or 'Hemispherx') announced today that it anticipates filing its 2016 first quarter financial results ...
05/12/16 05:34 AMHemispherx BioPharma, Inc (HEB) Short Interest Down 38.9% in April - Washington News Wire - Washington News WireHemispherx BioPharma, Inc (HEB) Short Interest Down 38.9% in AprilWashington News WireHemispherx BioPharma logo Hemispherx BioPharma, Inc (NYSE:HEB) saw a large drop in short interest during the month of April. As of April 29th, there was short interest totalling 334,831 shares, a drop of 38.9% from the April 15th total of 547,690 ...Hemispherx Biopharma Incorporated (NYSEMKT:HEB) Shorted Shares Increased 7.24% After Market SellingFranklin Independentall 3 news articles »
05/05/16 05:17 AMUpdated Trading Report: Sanofi (NYSE:SNY) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB) - Street Updates - Updated Trading Report: Sanofi (NYSE:SNY) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB)Street UpdatesIn the past trading session, Hemispherx BioPharma, Inc. (NYSEMKT:HEB) highlighted upward shift of +2.3651% or +0.0032 points to $0.1385. The company traded a volume of 1.03 million shares over average volume of 757.31 thousand shares. Trailing ...and more »
05/02/16 05:03 AMHemispherx Biopharma Incorporated (NYSEMKT:HEB) Short Interest Increased By 7.24% - B.O.D.Y Confidential - Hemispherx Biopharma Incorporated (NYSEMKT:HEB) Short Interest Increased By 7.24%B.O.D.Y ConfidentialHemispherx Biopharma, Inc. is a specialty pharmaceutical firm engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The company ...and more »
04/28/16 05:17 AMToday's Watch List: Civista Bancshares, Inc. (NASDAQ:CIVB), Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Citigroup ... - KC Register - Today's Watch List: Civista Bancshares, Inc. (NASDAQ:CIVB), Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Citigroup ...KC RegisterOn April 20, Hemispherx Biopharma, Inc. (NYSEMKT:HEB) announced that it has signed a consulting agreement with Huron Consulting Group, a global consultancy with decades of experience in the life sciences market, to advance the company's strategic ...
04/28/16 05:17 AMHealthcare Stocks in Momentum: Hemispherx BioPharma (HEB), Laboratory Corp. of America Holdings (LH) - News Oracle - Healthcare Stocks in Momentum: Hemispherx BioPharma (HEB), Laboratory Corp. of America Holdings (LH)News OracleHemispherx BioPharma, Inc (NYSEMKT:HEB) surged 12.98% yesterday and closed at $0.154. The company's market capitalization is at $38.55 Million with an average trading volume of 534,788.00. The total number of Outstanding Shares Held by the ...Stocks to Track: Hemispherx Biopharma, Inc. (HEB), Dollar General Corporation (DG), Express Inc. (EXPR)iStreetWireall 2 news articles »
04/27/16 05:53 AMLatest Stock's Price Updates: Hemispherx BioPharma, Inc. (NYSEMKT:HEB) , Atossa Genetics Inc. (NASDAQ:ATOS) - Street Updates - Latest Stock's Price Updates: Hemispherx BioPharma, Inc. (NYSEMKT:HEB) , Atossa Genetics Inc. (NASDAQ:ATOS)Street UpdatesOn 4/26/2016, Hemispherx BioPharma, Inc. (NYSEMKT:HEB) ended trading session higher at $0.1541 with +12.9765%. The company traded a volume of 2.09 million shares as comparison to average volume of 727.02 thousand shares. During the 52 –week ...
04/20/16 07:41 AMHemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon® and Ampligen® - [at noodls] - PHILADELPHIA, April 20, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the 'Company' or 'Hemispherx') announced that it has signed a consulting agreement with Huron Consulting Group, a global ...
04/18/16 01:35 PMTerminated CEO, Philadelphia biotech firm settle wrongful termination lawsuit -
04/16/16 09:13 AMHere is What Institutional Investors Think About Hemispherx Biopharma Inc (NYSEMKT:HEB) - RiversideGazette.com - Here is What Institutional Investors Think About Hemispherx Biopharma Inc (NYSEMKT:HEB)RiversideGazette.comHemispherx Biopharma Inc (NYSEMKT:HEB) institutional sentiment decreased to 1 in 2015 Q3. Its down -2.00, from 3 in 2015Q2. The ratio worsened, as 6 funds opened new and increased equity positions, while 2 cut down and sold their holdings in ...
04/12/16 09:04 AMShort Interest in Hemispherx BioPharma, Inc (HEB) Declines By 13.9% - Washington News Wire - Washington News WireShort Interest in Hemispherx BioPharma, Inc (HEB) Declines By 13.9%Washington News WireHemispherx BioPharma logo Hemispherx BioPharma, Inc (NYSE:HEB) was the recipient of a significant drop in short interest in March. As of March 31st, there was short interest totalling 510,694 shares, a drop of 13.9% from the March 15th total of 593,182 ...and more »
04/08/16 08:45 AMHemispherx Biopharma Incorporated (NYSEMKT:HEB) Short Interest Decreased By 6.71% - RiversideGazette.com - Hemispherx Biopharma Incorporated (NYSEMKT:HEB) Short Interest Decreased By 6.71%RiversideGazette.comThe short interest to Hemispherx Biopharma Incorporated's float is 0.24%. The stock increased 2.66% or $0.003 on April 7, hitting $0.135. About 226,874 shares traded hands. Hemispherx BioPharma, Inc (NYSEMKT:HEB) has declined 27.78% since ...
About Hemispherx BioPharma

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's flagship products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS (Chronic Fatigue Syndrome). The Company's Alferon LDO (Low Dose Oral) is an experimental liquid natural interferon for oral administration.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: HEB
  • CUSIP:
Key Metrics:
  • Previous Close: $0.11
  • 50 Day Moving Average: $0.1180
  • 200 Day Moving Average: $0.1198
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $28.11M
  • Current Quarter EPS Consensus Estimate: $0.0000 EPS
Additional Links:
Hemispherx BioPharma (NYSE:HEB) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha